PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
149.60%
Cash & equivalents yoy growth at least 1.5x AXSM's 0.70%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
149.60%
Cash + STI yoy ≥ 1.5x AXSM's 0.70%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.42%
≥ 1.5x AXSM's 8.49%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
835.01%
Below half AXSM's -3.53%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1079.37%
≥ 1.5x AXSM's 1.11%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
135.47%
≥ 1.5x AXSM's 7.23%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
69.91%
Above 1.5x AXSM's 6.97%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-41.82%
Less than half of AXSM's 15392.73%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-49.13%
Less than half of AXSM's 14.15%. David Dodd sees fewer expansions in other current obligations.
-44.50%
Less than half of AXSM's 40.25%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-44.50%
Less than half of AXSM's 4.28%. David Dodd sees far fewer liability expansions relative to competitor.
7.98%
Higher Common Stock (Book Value) Growth compared to AXSM's zero value, indicating worse performance.
4.22%
Below half AXSM's -4.06%. Michael Burry suspects major net losses or high dividends vs. competitor.
-271.57%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
132.15%
≥ 1.5x AXSM's 37.35%. David Dodd sees stronger capital base growth than competitor.
135.47%
≥ 1.5x AXSM's 7.23%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-41.82%
Less than half of AXSM's 2.81%. David Dodd sees less overall debt expansion vs. competitor.
-152.72%
Less than half of AXSM's 4.12%. David Dodd sees better deleveraging or stronger cash buildup than competitor.